All In Biotech

Drug Trial Radar · NCT06322342

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

A Multi-Center, Phase 2, Open Label, Ascending Dose Study to Evaluate the Safety and Efficacy of RVP-001 and to Identify an Appropriate Dose to Detect CNS Lesions in Adult Patients

Last checked: Nov 20, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Aug 15, 2024

Primary completion

Dec 19, 2025

Study completion Dec 19, 2025

Sponsor

Lead sponsor
Reveal Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
Mar 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis. The goal of this study is to assess safety, efficacy, and pharmacokinetics of RVP-001 at three dose levels. The study will also compare RVP-001 imaging to gadolinium-based contrast agent (GBCA) imaging. A single dose of RVP-001 will be administered to each subject. Subjects will have known gadolinium-enhancing CNS lesions and will have a gadolinium-based contrast agent-enhanced MRI of the brain 2-14 days before receiving RVP-001 with imaging. The ultimate goal of this research program is development of a gadolinium-free alternative to current general purpose MRI contrast agents.

Conditions

  • Central Nervous System (CNS) Lesions
  • Brain Metastases
  • Brain Neoplasms
  • Brain Neoplasms, Benign
  • Brain Tumor, Primary
  • Brain Tumor, Recurrent
  • Brain Tumors
  • Brain Cancer
  • Brain Tumor
  • Brain Neoplasm, Primary
  • Multiple Sclerosis
  • Multiple Sclerosis Brain Lesion
  • Neurofibroma
  • Acoustic Neuroma
  • CNS Tumor
  • CNS Lesion
  • CNS Metastases
  • CNS Cancer
  • CNS Lymphoma
  • Von Hippel Lindau
  • Meningioma
  • Glioma
  • Schwannomas
  • Neuroinflammation
  • Neoplasia

Interventions

  • RVP-001Drug

    MRI contrast agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: From time of dosing to 7 days post dose
  2. Lesion visualization criteria for RVP-001 enhanced MRI compared to unenhanced MRITime frame: 1 day
  3. Lesion visualization criteria for RVP-001 compared to gadolinium-based contrast agent (GBCA)Time frame: 1 day

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • University of Missouri

    Columbia, Missouri

  • Duke University Medical Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.